Loading
CB-101 is a three-armed antibody from XTOP Biotherapeutics that steers T cells to tumour cells carrying both ROR1 and EpCAM, in laboratory development for colon, pancreatic and lung cancers.
CB-101 is the lead programme of XTOP Biotherapeutics, built on its CrossBody platform and described on its pipeline page as a tumour-specific and tumour-associated antigen AND-gate trispecific T-cell engager for colon, pancreatic and lung cancers. The NCI SBIR award that funds its study (1R43CA310454-01A1) names ROR1, EpCAM and CD3 as its targets. No clinical trial is registered.
1.One arm of CB-101 binds ROR1 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CB-101" OR ABSTRACT:"CB-101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CB-101, not a curated reading list.
Shares ROR1 and the tag pipeline.
Shares EpCAM and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares EpCAM and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/